Every year, World Toilet Day is observed to raise awareness about the global sanitation crisis and encourage action to solve it. The goal set by the United Nation is to achieve safe toilets for all by 2023, as a part of their Sustainable Development Goals.

The UN also states that 3.5 billion people live without proper sanitation and many children also lose their lives due to poor sanitation and unsafe water. This is why World Toilet Day is observed to raise awareness on this issue.

Theme

This year, the theme for World Toilet Day 2024 is "Toilets - A Place for Peace'. This focuses on the growing threat to sanitation that is caused by conflict, climate change, disaster and neglect. When there is a threat to using toilets, it can lead to many health risks.

Not using toilets for too long may lead to Urinary Tract Infection or UTI. For many who do not have access to clean toilets do not drink enough liquid or hold pee for too long. Doctors suggest that holding in pee for too long can cause bacteria to multiply and lead to UTI. By not drinking enough water, your bladder fails to tell the body to pee often, and can cause the bacteria to spread through the urinary tract, which can lead to infection.

Symptoms of UTI:

• Burning or stinging feeling while urinating
• Pain in pelvis or lower abdomen
• Constant urge to empty the bladder
• Strong or foul smelling urine
• Consistently dark urine
• Blood in urine

Holding in pee for too long can also cause your bladder to stretch, making it difficult or even impossible for the bladder to contract and release pee normally. It can also damage your pelvic floor muscles or could lead to kidney stones.

World Toilet Day History And Significance

To prevent such conditions, it is important that everyone has access to clean and safe toilets. In terms of history, the day was established in 2001, by the World Toilet Organization (WTO), which was founded by Jack Sim. However, it was officially recognised by the UN in 2013. The Government of Singapore worked with WTO to create the first UN resolution called Sanitation for All.

India too promotes safe and hygiene toilet through its Swachh Bharat Yojna.

Punjab is implementing routine screening for HIV, Hepatitis B and Hepatitis C at government de-addiction and rehabilitation centres, highlighting the importance of testing for three major blood-borne infections in addiction patients.

The initiative, referred to as 'Triple H' screening, is being introduced under the state government’s Yudh Nashean Virudh campaign. The aim is to spot infections earlier, ensuring people undergoing treatment for substance use receive appropriate medical care when needed.

The initiative is meant to curb risks of HIV and Hepatitis B and C, especially in people who inject drugs and share contaminated needles and syringes. It is crucial as infections can also remain undetected for years.

Punjab Is Changing Its Screening Approach

Also read: H. pylori, HPV Among Five Infections Behind 1 In 8 Cancers Worldwide: Lancet

Until now, HIV and hepatitis screening at de-addiction facilities was largely conducted through medical camps, which were often held around every two months. While these camps provided testing opportunities, officials said that there was limited scope to track who had been tested, who had missed screening, and who needed further care.

Under the new system, screening will be integrated into the de-addiction and rehabilitation process. This could give people ample opportunities to get tested and allow those with positive results to be referred for intensive testing, treatment, and timely medical care.

Announcing the initiative, Health and Family Welfare Minister Dr. Balbir Singh spoke about the importance of early detection of blood-borne infections in those at high risk.

Dr. Singh said, “People with a history of injecting drug use face an increased risk of blood-borne infections, and that early detection is important for timely medical care and counselling.”

He also said that the initiative goes beyond treating patients struggling with drug addiction. The minister emphasised that this could indirectly help build better lives for themselves.

He added, “Under the leadership of Chief Minister Bhagwant Mann, Yudh Nashean Virudh is leading a revolution towards a stronger, healthier and prosperous Punjab. Our goal is not simply to help people overcome addiction, but also to enable them to lead healthier lives and contribute to society. By integrating HIV, Hepatitis B and Hepatitis C screening into de-addiction services, the Government is taking another important step towards ensuring that recovery leads to a meaningful and brighter future.”

Also read: 8-Weekly HIV Injections Keep Virus Suppressed Better Than Daily Pills In Adolescents: Lancet Study

Punjab Had Already Intensified HIV Screening

The latest announcement comes months after Punjab ordered HIV screening for people registered at its Outpatient Opioid Assisted Treatment (OOAT) centres.

In May, the state had 455 operational OOAT centres with 3,09,918 registered clients undergoing treatment for substance use.

That move came after findings from the National AIDS Control Organisation showed that Punjab recorded a 58.7% increase in annual new HIV infections between 2010 and 2024.

The report also found that 56% of newly detected HIV-positive cases in Punjab were linked with contaminated syringe use.

The state has also said testing for HIV, Hepatitis B and Hepatitis C is available free of cost at Aam Aadmi Clinics.

Earlier in August, Punjab announced the adoption of Nucleic Acid Testing (NAT) and Chemiluminescence Immunoassay (CLIA) technologies to strengthen the early detection of infections that are transmitted through infusions and improve blood safety.

Three scientists from the US and Germany have been awarded the 2026 Nobel Prize in Physiology or Medicine for optogenetics — a method that makes it possible to show how nerve cells shape memories, feelings and behaviors in the living brain.

The Prize was awarded to Karl Deisseroth, 54, from the US, and Peter Hegemann,71, and Georg Nagel, 73, from Germany, “for their discoveries concerning light-gated ion channels and optogenetics,” the Nobel Assembly at Karolinska Institutet said in a statement. A prize money of 12 million Swedish kronor will be shared equally between the laureates, it added.

At the Max Planck Institute for Biophysics, in Germany's Frankfurt, Peter and Georg discovered a protein called channelrhodopsin in a single-celled alga. Karl later transformed itinto a light-controlled switch for nerve cells.

The laureates have laid the foundation for a new era in neuroscience, the Nobel Assembly said.

Deisseroth is based at Stanford University in California, while Hegemann is from Humboldt University in Berlin and Nagel from the University of Wurzburg in Germany.

What Did Their Findings Show?

How the brain governs feelings, behaviors and bodily functions has long been a mystery, but optogenetics has fundamentally changed scientists’ understanding of the brain.

“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” said Per Svenningsson, Chair of the Nobel Committee for Physiology or Medicine.

In the 20th century, researchers began investigating which areas of the brain affect different functions. However, the methods available at the time could not establish causal relationships. The resulting picture of the brain was like a sketch map, filled with question marks and unknowns. Optogenetics has helped change that.

How Did Optogenetics Begin?

The discovery began with Hegemann, who wanted to understand how Chlamydomonas, a single-celled alga, swims towards a light source.

In the early 2000s, Hegemann and Nagel discovered channelrhodopsin, an algal protein with unique properties found on the surface of the cell.

They found that when exposed to blue light, a channel opens through the protein, allowing charged ions to flow into the cell and create an electrical impulse. They also found that when the protein was introduced into other cells, those cells became sensitive to light.

How Did Deisseroth Transform the Discovery?

Deisseroth then introduced the gene for channelrhodopsin into nerve cells from rats. By illuminating the cells with blue light, he was able to trigger a nerve signal.

He published this breakthrough in 2005. Two years later, he demonstrated that the light-controlled switch could work in the brains of living mice.

This method of controlling nerve signals with light is now known as optogenetics and has rapidly gained global impact.

Using optogenetics, researchers have been able to reveal neural circuits involved in specific memories, feelings and behaviours relevant to neurological and psychiatric disorders.

In clinical medicine, researchers are also using the method in attempts to restore sight in people with visual impairment.

All About the Nobel Prize

The Nobel Prize was first awarded on December 10, 1901, following the will of founder Alfred Nobel, which he signed in Paris in 1895.

So far, 116 Nobel Prizes in Physiology or Medicine have been awarded. The youngest medicine laureate was Frederick G. Banting, who was 31 when he received the award in 1923. The oldest was Peyton Rous, who was 87 when he received the award in 1966.

India’s first indigenously developed gender-neutral quadrivalent human papillomavirus (HPV) vaccine, Cervavac, has received prequalification from the World Health Organization (WHO), the Serum Institute of India announced today.

WHO prequalification marks an important regulatory milestone and opens the possibility of UN agencies procuring Cervavac and supplying it to eligible countries. It could also expand access to HPV vaccination for both boys and girls globally.

“WHO prequalification of Cervavac is an important step in strengthening the global response to HPV. This milestone reflects the effectiveness of the vaccine and creates the opportunity for countries to prevent HPV-related risks. We are pleased to see this indigenously developed vaccine reach this achievement, and look forward to contributing to immunization coverage, advancing global healthcare,” said Adar Poonawalla, Chief Executive Officer, Serum Institute of India, in a statement.

What Is Cervavac?

Cervavac is a recombinant quadrivalent HPV vaccine that targets HPV types 6, 11, 16 and 18.

India’s drug regulator, the Central Drugs Standard Control Organization (CDSCO), has already approved Cervavac vaccine for girls and boys aged 9 to 26 years. HPV types 16 and 18 are associated with several cancers, while types 6 and 11 are responsible for most genital warts.

In girls and women, Cervavac is indicated for the prevention of cervical, vulvar, vaginal and anal cancers caused by HPV types 16 and 18, as well as genital warts caused by types 6 and 11.

In boys and men, it is indicated for the prevention of anal cancer caused by HPV types 16 and 18 and genital warts caused by types 6 and 11.

The vaccine was developed with support from the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC), in collaboration with the WHO’s International Agency for Research on Cancer (IARC) and the Gates Foundation.

The WHO prequalification is the 32nd received by the Serum Institute for its products and biologicals.

Who Is Eligible for Cervavac?

Cervavac is approved in India for girls and boys aged 9 to 26 years.

Children aged 9 to 14 years receive the vaccine as a two-dose schedule, with doses given at 0 and six months. Those aged 15 to 26 years receive three doses at 0, two and six months.

The vaccine is administered intramuscularly and is available in 0.5 mL single-dose and 1 mL two-dose vial presentations.

Could Cervavac Join India’s Vaccination Program?

Cervavac is yet to be incorporated into India’s Universal Immunization Program (UIP).

The vaccine is currently being studied as a single-dose vaccine. An ongoing study led by the Indian Council of Medical Research (ICMR) is assessing whether one dose produces sufficient and sustained antibody protection compared with a single dose of Gardasil.

The results are expected in 2027. Evidence from the study could help determine whether Cervavac can be recommended as a single-dose vaccine and considered for inclusion in India’s national immunization program.

Rajesh Gokhale, secretary of the Department of Biotechnology, said Cervavac was initially not introduced into the national program because it required two doses. “The single-dose will come in (to the national program) after it has been clinically tested,” he was quoted as saying.

Cervavac currently costs around Rs 2,000 in the private market, although its potential price for government procurement has not been disclosed.

India’s HPV Vaccination Drive And Cervical Cancer Burden

India launched a nationwide HPV vaccination campaign for 14-year-old girls in February 2026, using Gardasil-4, developed by Merck.

Cervavac was launched in India in September 2022 after Phase 2/3 trials found it to be non-inferior to Gardasil. At the time, Serum Institute had indicated that the vaccine could potentially be supplied to the government at a substantially lower price through public procurement.

Cervical cancer remains a major public health concern in India, with about 80,000 new cases reported annually and more than 42,000 deaths. India accounts for roughly one-fifth of the global cervical cancer burden.